» Articles » PMID: 11196105

Hepatocellular Carcinoma Despite Long-term Survival in Chronic Tyrosinaemia I

Overview
Publisher Wiley
Date 2001 Feb 24
PMID 11196105
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Tyrosinaemia I (fumarylacetoacetate hydrolase deficiency) is an autosomal recessive inborn error of tyrosine metabolism that produces liver failure in infancy or a more chronic course of liver disease with cirrhosis, often complicated by hepatocellular carcinoma, in childhood or early adolescence. We studied a 37-year-old woman with tyrosinaemia I whose severe liver disease in infancy and rickets during childhood resolved with dietary therapy. From 14 years of age she resumed an unrestricted diet with the continued presence of the biochemical features of tyrosinaemia, yet maintained normal liver function. In adult years she accumulated only small amounts of succinylacetone. Despite this evolution to a mild biochemical and clinical phenotype, she eventually developed hepatocellular carcinoma. Her fumarylacetoacetate hydrolase genotype consists of a splice mutation, IVS6-1g>t, and a novel missense mutation, Q279R. Studies of resected liver demonstrated the absence of hydrolytic activity and of immunological expression of fumarylacetoacetate hydrolase in liver tumour. In nontumoral areas, however, 53% of normal hydrolytic activity and immunologically present fumarylacetoacetate hydrolase was found. This case demonstrates the high risk of liver cancer in tyrosinaemia I even in a seemingly favourable biological environment.

Citing Articles

Smad2/3/4 complex could undergo liquid liquid phase separation and induce apoptosis through TAT in hepatocellular carcinoma.

Li J, Wang W, Li S, Qiao Z, Jiang H, Chang X Cancer Cell Int. 2024; 24(1):176.

PMID: 38769521 PMC: 11106862. DOI: 10.1186/s12935-024-03353-x.


A False-Negative Newborn Screen for Tyrosinemia Type 1-Need for Re-Evaluation of Newborn Screening with Succinylacetone.

Dijkstra A, Evers-van Vliet K, Heiner-Fokkema M, Bodewes F, Bos D, Zsiros J Int J Neonatal Screen. 2023; 9(4).

PMID: 38132825 PMC: 10744279. DOI: 10.3390/ijns9040066.


Short-term nitisinone discontinuation of hereditary tyrosinemia type 1 mice causes metabolic alterations in glutathione metabolism/biosynthesis and multiple amino acid degradation pathways.

Haaike C, Brendan N, Sven V, Andrew D, Lionel M, Georges C Genes Dis. 2023; 10(5):1759-1762.

PMID: 37492745 PMC: 10363636. DOI: 10.1016/j.gendis.2022.11.013.


Proteomic analysis of fatty liver induced by starvation of medaka fish larvae.

Ikeda T, Ishikawa T, Ninagawa S, Okada T, Ono M, Mori K Cell Struct Funct. 2023; 48(2):123-133.

PMID: 37380437 PMC: 10915113. DOI: 10.1247/csf.23014.


Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma.

Zhou Y, Li X, Long G, Tao Y, Zhou L, Tang J Front Immunol. 2022; 13:994259.

PMID: 36341373 PMC: 9633179. DOI: 10.3389/fimmu.2022.994259.


References
1.
STOWERS J, DENT C . Studies on the mechanism of the Fanconi syndrome. Q J Med. 2010; 16(4):275-90. View

2.
Tanguay R, Valet J, Lescault A, Duband J, Laberge C, Lettre F . Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). Am J Hum Genet. 1990; 47(2):308-16. PMC: 1683717. View

3.
Kvittingen E, Rootwelt H, Brandtzaeg P, Bergan A, Berger R . Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect. J Clin Invest. 1993; 91(4):1816-21. PMC: 288163. DOI: 10.1172/JCI116393. View

4.
WEINBERG A, MIZE C, WORTHEN H . The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr. 1976; 88(3):434-8. DOI: 10.1016/s0022-3476(76)80259-4. View

5.
Paradis K, Weber A, Seidman E, Larochelle J, Garel L, Lenaerts C . Liver transplantation for hereditary tyrosinemia: the Quebec experience. Am J Hum Genet. 1990; 47(2):338-42. PMC: 1683709. View